全文获取类型
收费全文 | 60775篇 |
免费 | 5017篇 |
国内免费 | 1400篇 |
专业分类
耳鼻咽喉 | 623篇 |
儿科学 | 1667篇 |
妇产科学 | 1462篇 |
基础医学 | 7514篇 |
口腔科学 | 976篇 |
临床医学 | 8627篇 |
内科学 | 10341篇 |
皮肤病学 | 1134篇 |
神经病学 | 4847篇 |
特种医学 | 1569篇 |
外国民族医学 | 13篇 |
外科学 | 6430篇 |
综合类 | 4407篇 |
现状与发展 | 4篇 |
一般理论 | 86篇 |
预防医学 | 5947篇 |
眼科学 | 1494篇 |
药学 | 4217篇 |
18篇 | |
中国医学 | 1113篇 |
肿瘤学 | 4703篇 |
出版年
2023年 | 547篇 |
2022年 | 973篇 |
2021年 | 1902篇 |
2020年 | 1462篇 |
2019年 | 1689篇 |
2018年 | 1859篇 |
2017年 | 1523篇 |
2016年 | 1640篇 |
2015年 | 2002篇 |
2014年 | 2491篇 |
2013年 | 2987篇 |
2012年 | 4371篇 |
2011年 | 4421篇 |
2010年 | 2489篇 |
2009年 | 2176篇 |
2008年 | 3614篇 |
2007年 | 3743篇 |
2006年 | 3720篇 |
2005年 | 3615篇 |
2004年 | 3051篇 |
2003年 | 2802篇 |
2002年 | 2569篇 |
2001年 | 1027篇 |
2000年 | 999篇 |
1999年 | 1006篇 |
1998年 | 837篇 |
1997年 | 644篇 |
1996年 | 554篇 |
1995年 | 552篇 |
1994年 | 464篇 |
1993年 | 394篇 |
1992年 | 442篇 |
1991年 | 399篇 |
1990年 | 387篇 |
1989年 | 370篇 |
1988年 | 322篇 |
1987年 | 283篇 |
1986年 | 299篇 |
1985年 | 271篇 |
1984年 | 209篇 |
1983年 | 181篇 |
1982年 | 188篇 |
1981年 | 188篇 |
1980年 | 185篇 |
1979年 | 126篇 |
1978年 | 108篇 |
1977年 | 112篇 |
1976年 | 104篇 |
1974年 | 112篇 |
1972年 | 96篇 |
排序方式: 共有10000条查询结果,搜索用时 158 毫秒
41.
42.
43.
Martin J. Kurian Peter J. Rentzepis Ann M. Carracher Kelly L. Close 《Journal of Diabetes》2019,11(9):700-702
Martin J. Kurian, Peter J. Rentzepis, Ann M. Carracher, and Kelly L. Close are of Close Concerns ( http://www.closeconcerns.com ), a healthcare information company focused exclusively on diabetes and obesity care. Close Concerns publishes Closer Look, a periodical that brings together news and insights in these areas. Each month, the Journal of Diabetes includes this News feature, in which Kurian, Rentzepis, Carracher, and Close review the latest developments relevant to researchers and clinicians. 相似文献
44.
Joseph Biederman Haitao Gao Ann K Rogers Thomas J Spencer 《Neuropsychopharmacology》2006,60(10):1106-1110
BACKGROUND: The validity of parent reports regarding children's attention-deficit/hyperactivity disorder (ADHD) symptoms has been questioned. This study assessed whether parent reports were as sensitive as teacher reports to document change in ADHD symptoms during clinical trials with atomoxetine. METHODS: Data were compared from two randomized, double-blind, placebo-controlled clinical trials of atomoxetine using different versions (parent or teacher) of the same rating scale (Attention-Deficit/Hyperactivity Disorder Rating Scale-IV [parent or teacher] Version: Investigator Administered and Scored - ADHD RS). Exclusion criteria included history of bipolar disorder, psychosis, seizures, alcohol abuse, or positive drug screen. Patients (6-16 years old) were treated with atomoxetine (titrated to a maximum dose of 1.8 mg/kg/day) administered once daily for up to 7 weeks. Parent and teacher ratings were compared using an analysis of covariance (ANCOVA) model. RESULTS: The analysis (n = 318) showed that treatment effects (mean change, baseline to endpoint) were similar between parent and teacher ratings (total, p = .762; inattention, p = .519; hyperactive/impulsive, p = .955). Effect sizes also were similar based on total scores (parent ratings = .69; teacher ratings = .63). CONCLUSIONS: Parent reports are as sensitive as teacher reports in assessing the efficacy of long-acting pharmacologic treatment for ADHD in children during clinical trials using the nonstimulant atomoxetine. 相似文献
45.
46.
Jonathan Halford Gandis Mazeika Susan Slifer Marcy Speer Ann M Saunders Warren J Strittmatter Joel C Morgenlander 《Movement disorders》2006,21(4):540-542
Ninety-seven inpatients with tardive dyskinesia (average AIMS score = 13), the majority of whom were schizophrenic, were studied. Forty patients were Caucasian, and 57 were African-American. The APOE genotypes of these patients were compared to previously published genotypes of controls and with previously published studies of APOE genotypes in patients with schizophrenia. There were no significant differences in APOE allele frequencies comparing the African-American tardive dyskinesia population and the African-American control groups. In contrast, significant (< 0.05) P values were obtained comparing the Caucasian tardive dyskinesia population to the Caucasian controls, when comparing allele frequencies and genotypic frequencies. This study suggests that Caucasians bearing an APOE2 allele are at increased risk of developing tardive dyskinesia, whereas African-Americans are not. APOE genotype-specific risks of both tardive dyskinesia and Alzheimer's disease that vary across populations could be due to recruitment of patients or controls or could be due to modifying effects of differing genetic or environmental backgrounds. The mechanism by which the APOE2 allele increases risk of tardive dyskinesia is not known. Further information about the mechanisms of increased risk of tardive dyskinesia could result in stratification of prescribing practices weighing the costs of medications against the relative risk of side effects. 相似文献
47.
Mary Ann Richardson Helen M Chao Laura L Read James D Clelland Raymond F Suckow 《American journal of medical genetics. Part B, Neuropsychiatric genetics》2006,(2):195-197
Phenylketonuria (PKU), an inborn error of phenylalanine metabolism, has been shown to be a risk factor for tardive dyskinesia (TD). In male psychiatric patients there was a significant relationship between TD and measures of plasma phenylalanine following ingestion of a standardized phenylalanine dose that was indicative of higher brain availability of phenylalanine in patients with TD. In addition, a medical food formulation consisting of branched chain amino acids, which compete with phenylalanine for transport across the blood-brain barrier, has been demonstrated to be an efficacious treatment for TD. Cumulatively these findings suggested that TD was related to phenylalanine metabolism and thus that sequence variants in the gene for phenylalanine hydroxylase (PAH), the rate-limiting enzyme in the catabolism of phenylalanine, could be associated with TD susceptibility. Genetic screening of PAH in a group of 123 psychiatric patients revealed ten sequence polymorphisms and two mutations, but none appeared to be a significant risk factor for TD. 相似文献
48.
Katharine R. Owen Mollie Donohoe Sian Ellard Andrew T. Hattersley 《Diabetic medicine》2003,20(10):823-827
Background Familial partial lipodystrophy (FPLD) is a monogenic form of diabetes characterised by a dominantly inherited disorder of adipose tissue associated with the loss of subcutaneous fat from the limbs and trunk, with excess fat deposited around the face and neck. The lipodystrophy causes severe insulin resistance, resulting in acanthosis nigricans, diabetes, dyslipidaemia, and increased risk of cardiovascular disease. Preliminary results from animals and man suggest that increasing subcutaneous fat by treatment with thiazolidinediones should improve insulin resistance and the associated features of this syndrome. Case report We report a 24-year-old patient with FPLD caused by a mutation in the LMNA gene (R482W) treated with 12 months of rosiglitazone. Subcutaneous fat increased following rosiglitazone treatment as demonstrated by a 29% generalised increase in skin-fold thickness. Leptin levels increased from 5.8 to 11.2 ng/ml. Compared with treatment on Metformin, there was an increase in insulin sensitivity (HOMA S% 17.2–31.6) but no change in glycaemic control. The lipid profile worsened during the follow-up period. Conclusion This initial case suggests that, for modification of cardiovascular risk factors, there are no clear advantages in treating patients with FPLD with rosiglitazone despite increases in subcutaneous adipose tissue. Larger series will be needed to identify moderate beneficial effects and treatment may be more effective in patients with generalised forms of lipodystrophy. 相似文献
49.
Kalaichelvi Ganesalingam Ann Sanson Vicki Anderson Keith Owen Yeates 《Journal of the International Neuropsychological Society》2006,12(5):609-621
This study examined the impact of childhood traumatic brain injury (TBI) on self-regulation and social and behavioral functioning, and the role of self-regulation as a predictor of children's social and behavioral functioning. Participants included 65 children with moderate to severe TBI and 65 children without TBI, all between 6 and 11 years of age. Self-regulation and social and behavioral functioning were assessed 2 to 5 years following injury. Children with TBI displayed deficits in self-regulation and social and behavioral functioning, after controlling for socioeconomic status (SES), although the magnitude of the deficits was not related to injury severity. Self-regulation accounted for significant variance in children's social and behavioral functioning, after controlling for SES and group membership. Self-regulation may be an important determinant of children's social and behavioral functioning following TBI. 相似文献
50.